Sepio Capital LP Has $3.42 Million Holdings in Johnson & Johnson $JNJ

Key Points

• Sepio Capital LP reduced its holdings in Johnson & Johnson shares by 13.4%, now owning 20,614 shares valued at approximately $3.42 million.
• Johnson & Johnson reported earnings of $2.77 per share for the most recent quarter, surpassing the consensus estimate of $2.68, with revenues of $23.74 billion.
• The company announced a dividend of $1.30 per share, representing a 2.9% yield and a payout ratio of 55.61%.

Sepio Capital LP lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,614 shares of the company's stock after selling 3,199 shares during the period. Sepio Capital LP's holdings in Johnson & Johnson were worth $3,419,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of JNJ. Brighton Jones LLC lifted its holdings in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares during the period. Hudson Value Partners LLC raised its stake in Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after buying an additional 1,022 shares during the last quarter. Focus Partners Wealth raised its stake in Johnson & Johnson by 15.6% during the fourth quarter. Focus Partners Wealth now owns 1,033,959 shares of the company's stock worth $149,531,000 after buying an additional 139,500 shares during the last quarter. Graham Capital Management L.P. bought a new position in Johnson & Johnson during the fourth quarter worth $16,100,000. Finally, Gen Wealth Partners Inc raised its stake in Johnson & Johnson by 3.6% during the fourth quarter. Gen Wealth Partners Inc now owns 13,607 shares of the company's stock worth $1,968,000 after buying an additional 468 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.3%

NYSE:JNJ opened at $178.20 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a 50-day moving average of $168.57 and a 200-day moving average of $160.78. The company has a market cap of $429.15 billion, a PE ratio of 19.06, a PEG ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's payout ratio is presently 55.61%.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of analyst reports. Bank of America lifted their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. UBS Group lifted their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada lifted their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $176.29.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.